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Abstract
Introduction: Epigenetic modifications such as aberrant DNA methylation has long been associated with tumorogenesis.
Little is known, however, about how these modifications appear in cancer progression. Comparing the methylome of breast
carcinomas and locoregional evolutions could shed light on this process.
Methods: The methylome profiles of 48 primary breast carcinomas (PT) and their matched axillary metastases (PT/AM pairs,
20 cases), local recurrences (PT/LR pairs, 17 cases) or contralateral breast carcinomas (PT/CL pairs, 11 cases) were analyzed.
Univariate and multivariate analyzes were performed to determine differentially methylated probes (DMPs), and a similarity
score was defined to compare methylation profiles. Correlation with copy-number based score was calculated and
metastatic-free survival was compared between methods.
Results: 49 DMPs were found for the PT/AM set, but none for the others (FDRv 5% ). Hierarchical clustering clustered 75%
of the PT/AM, 47% of the PT/LR, and none of the PT/CL pairs together. A methylation-based score (MS) was defined as a
clonality measure. The PT/AM set contained a high proportion of clonal pairs while PT/LR pairs were evenly split between
high and low MS score, suggesting two groups: true recurrences (TR) and new primary tumors (NP). CL were classified as
new tumors. MS score was significantly correlated with copy-number based scores. There was no significant difference
between the metastatic-free survival of groups of patients based on different classifications.
Conclusion: Epigenomic alterations are well suited to study clonality and track cancer progression. Methylation-based
classification of TR and NP performed as well as clinical and copy-number based methods suggesting that these
phenomenons are tightly linked.
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Introduction
Breast conservative therapy, consisting in a partial mastectomy
followed by whole breast irradiation, is the standard treatment for
patients with early stage breast cancer. Overall survival is not
significantly different from more physically and psychologically
aggressive treatments such as mastectomy [1]. However, patients
relapse within 10 years in the same breast as the primary tumor
(PT) in approximately 6 % of cases [2], and within 5 years in the
contralateral breast in approximately 3:5% of cases [3] or more in
BRCA1/2 mutation carriers [4]. Moreover, at the time of
diagnosis, early stage breast cancers have already spread to
axillary lymph nodes in roughly 30 % of cases [5].
These different types of locoregional evolutions have different
implications in terms of survival and treatments. Axillary
metastases (AM) is usually predictive of poor survival [6] and is
considerably worsen in triple negative breast cancers [7]. Local
recurrences (LR) have been tightly linked with a greater risk of
distant metastasis [8]. Veronesi et al. [9] distinguished two
categories of local recurrences: true recurrences (TR), correspond-
ing to re-growth of resistant cells after initial treatment, and new
primary tumors (NP), corresponding to de novo cancer. This
classification is of potential interest to define adapted treatment
scheme, as NP are considered to have an improved survival
compared to TR [10]. Contralateral breast cancers (CL) are also
an heterogeneous entity depending on the synchronism with the
primary tumor. Synchronous bilateral breast cancers are devel-
oped at the same time, with the same genetic, environmental and
hormonal background as the PT. Metachronous CL are usually
PLOS ONE | www.plosone.org 1 August 2014 | Volume 9 | Issue 8 | e103986
T
a
b
le
1
.
Su
m
m
ar
iz
e
d
P
T
/L
R
C
lin
ic
al
an
d
h
is
to
lo
g
ic
al
fe
at
u
re
s.
P
T
L
o
ca
l
R
e
cu
rr
e
n
ce
D
is
co
rd
a
n
ce
P
a
ir
C
o
r
A
g
e
T
y
p
e
G
ra
d
e
E
R
P
R
H
E
R
2
T
y
p
e
G
ra
d
e
E
R
P
R
H
E
R
2
L
o
c
1
1
2
3
.3
D
3
-
+
-
D
2
+
+
-
1
ER
2
3
4
2
.9
D
3
+
+
-
D
3
+
+
-
1
3
1
1
4
9
.3
L
3
-
-
-
D
3
-
-
+
1
H
ER
2
4
1
6
4
8
.8
D
2
+
+
-
D
1
+
+
-
1
5
1
2
4
9
.3
L
2
+
+
-
L
2
+
-
-
0
P
R
6
1
3
4
5
.4
D
2
+
+
-
D
2
+
+
-
1
7
1
5
4
6
.5
D
2
+
+
-
D
2
+
+
-
1
8
2
4
2
.4
D
2
+
+
-
L
1
+
+
N
A
1
9
4
4
8
.6
L
1
+
+
-
L
2
+
+
-
1
1
0
1
4
4
4
L
2
+
+
-
L
2
-
+
-
1
ER
1
1
1
8
N
A
D
3
-
-
N
A
D
2
+
+
N
A
1
ER
/P
R
1
2
2
0
4
7
.5
D
3
-
-
+
D
3
-
-
+
0
1
3
2
1
4
6
.7
D
2
+
-
N
A
D
3
+
-
-
1
1
4
2
3
3
1
D
2
-
-
-
D
3
-
-
-
1
1
5
2
4
4
8
.1
D
3
-
-
-
D
3
-
-
-
1
1
6
2
5
4
3
.3
D
3
+
+
-
D
3
+
+
-
1
1
7
2
6
3
0
.8
D
3
-
-
-
D
3
-
-
-
1
C
o
r
(C
o
rr
e
sp
o
n
d
e
n
ce
):
co
rr
e
sp
o
n
d
e
n
ce
n
u
m
b
e
r
w
it
h
th
e
B
o
lle
t/
Se
rv
an
t
co
h
o
rt
fr
o
m
[1
6
],
T
y
p
e
:
h
is
to
lo
g
ic
al
ty
p
e
o
f
th
e
tu
m
o
r
(D
=
d
u
ct
al
,
L
=
lo
b
u
la
r)
,
G
ra
d
e
:
A
g
g
re
ss
iv
e
n
e
ss
o
f
th
e
tu
m
o
r
(1
to
3
),
E
R
:
p
re
se
n
ce
o
f
e
st
ro
g
e
n
re
ce
p
to
rs
,
P
R
:
p
re
se
n
ce
o
f
p
ro
g
e
st
e
ro
n
e
re
ce
p
to
rs
,
H
E
R
2
:
p
re
se
n
ce
o
f
H
ER
2
re
ce
p
to
rs
,
L
o
c
(L
o
ca
ti
o
n
):
1
if
th
e
re
cu
rr
e
n
ce
w
as
lo
ca
te
d
le
ss
th
an
4
cm
fr
o
m
th
e
P
T
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
3
9
8
6
.t
0
0
1
Epigenomic Alterations in Breast Tumors and Their Recurrences
PLOS ONE | www.plosone.org 2 August 2014 | Volume 9 | Issue 8 | e103986
treated as new cancers [11] although a rare portion are considered
as metastases. Overall, CL are still associated with a greater risk of
metastasis compared to patients without CL [12].
Differences between the PT and either the AM, the LR or the
CL have been studied at the genomic, transcriptomic and
proteomic levels. Ellsworth et al. [13] showed an overall frequency
of allelic imbalance greater in PT than in AM. Weigelt et al. [14]
explored the gene expression profile of PT and their matched AM
but were not able to identify a subset of genes to discriminate
them, while Feng et al. [15] identified a set of 79 genes able to
differentiate PT from matched AM. Studies between PT and LR
have mainly focused on distinguishing TR and NP. A criterion
based on clinical and pathological features was first established but
judged insufficiently robust for most clinical applications. Several
studies investigated the difference between TR and NP based on
pangenomic analyzes of DNA copy number alterations (CNA)
[16,17], intratumoral immune responses [18], loss of heterozigos-
ity [19], to p53 analysis [20], or X-chromosome inactivation [21].
Finally, studies of PT and CL highlighted the role of synchronism
of the CL. Similarity measures based on DNA copy number
profiles [22] or allelic imbalance [23] showed a higher level of
similarity between PT and synchronous CL compared to PT and
metachronous CL.
Epigenetic modifications in cancer has recently been the topic of
many studies. In particular the link between hypermethylation and
gene silencing is well known [24–26]. Several studies have then
focused to describe cancer as an epigenetic disease. Baylin et al.
[27] have shown that aberrant hypermethylation of specific
regions, dominantly CpG islands, are linked with the silencing of
tumor suppressor genes and that this phenomenon is present in
most cancers. Laird [28], Ehrlich [29] and Das [30] suggested that
a global hypomethylation phenomenon was also linked with
tumorogenesis. Jones [31] made a complete review of the
hallmarks of epigenomics associated with cancer. Moreover,
DNA methylation is conserved during cell division [26,32] and
could serve as a measure for clonality between cells in the
classification of LR as either TR or NP.
In this study, epigenetic differences as well as similarities
between PTs and either their AMs, LRs or CLs are analyzed. In
the first part, univariate and multivariate analyzes are performed
between the methylome profiles of primary tumors and their
matched recurrences to observe recurrent patterns in cancer
progression. Then in the second part, epigenome-wide similarity
analyzes on the same samples is performed to observe clonality
between tumor cells.
Results
Methylation differences between PT and their matched
metastasis or recurrence
A collection of 17 PT/LR pairs, 11 PT/CL pairs, and 20 PT/
AM pairs was analyzed. The methylation data are available in the
GEO database record number: GSE44870. Tables 1, 2 and 3
detail the summarized clinico-histopathological properties of each
sample. Some of the PT/LR samples match in part the cohort
studied by Bollet et al. [16], and the corresponding sample
numbers from both studies are provided in Table 2. Tables S1, S2
and S3 provide more detailed characteristics.
Within each of the three cohorts, pairs of tumors including a PT
and a metastatic or relapse sample can be used to investigate
whether particular patterns in methylation profiles can serve as
marker for cancer progression.
Within each cohort, investigations were made to detect
differences at the methylome level between PT and the
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corresponding matched metastasis (AM) or relapse samples (LR or
CL). Using a paired Wilcoxon test, 49 probes significantly
differentially methylated were found between PT and AM samples
(at a 5% FDR level). The top 50 probes ranked by p-value and the
corresponding genes are listed in Table 4. This suggests that a
general signal characteristic of cancer progression from PT to AM
might exist. However, no probe was found significantly differen-
tially methylated between PT and LR, and between PT and CL.
This may be due to the lack of cancer progression marker at the
methylation level between PT and relapse, to the fact that most
relapses may not be biologically related to the PT, or to the small
size of the cohort which limits the power of statistical tests. The top
50 probes ranked by p-value then by absolute methylation
variation between the primary tumor and its recurrence is also
provided in Tables S4 (PTLR) and S5 (PTCL). No overlap existed
between the three lists except for one gene (PI3K5R between the
PT/AM and PT/LR datasets). All the corresponding quantile-
quantile plots are available in Figure S1.
On the PT/AM cohort, the SVM model correctly identified the
PT and AM in 18 out of 20 held-out pairs (90% success rate, P-
value = 2:0  10{4) when considering the whole methylation
profile probes. The SVM model obtained after dimensionality
reduction by filtering the 22 most significant probes selected
according to a Wilcoxon test gave a 100% accuracy. As illustrated
in Figure 1, good accuracy was still achieved when considering an
increasing number of probes (Accuracy * 90% ). On the PT/LR
and PT/CL cohorts, however, the success rate was respectively
58% (10 out of 17 pairs, P-value = 0.31) and 27% (3 out of 11
pairs, P-value = 0.11) when taking all probes into account. Note
that these values are not significantly different from random guess.
Methylation conservation between PT and their matched
metastasis or recurrence
Instead of searching for differences between PT and their
matched metastasis or recurrence, which may characterize
markers for cancer progression, the study also focuses on
similarities between methylation profiles, which may be useful
for example to characterize clonality between a PT and a
recurrence. A hierarchical clustering was first performed for all
samples within each cohort to characterize the similarities between
real matched pairs compared to unrelated samples. The resulting
dendrograms are presented in Figure 2. Interestingly we see that
matched pairs of PT and metastasis/recurrence samples are
usually closer to each other than to any unrelated tissues in the
PT/AM cohort (15 out of 20, 75%), less often in the PT/LR
cohort (8 out of 17, 41%), and never in the PT/CL cohort. This
observation is consistent with decreasing proportions of real clonal
pairs from the PT/AM to the PT/CL set.
Another way to see this phenomenon is to assess statistically,
within each cohort, how the methylation distances between
matched pairs differ from the methylation distances between
unmatched pairs. Figure 3 displays the distributions of methyla-
tion distances for different sets of sample pairs compared to the
distance between matched sample pairs. We also display in
Figure 4 the boxplot of methylation distances by groups. Real
matched pairs between a PT and its corresponding metastasis or
recurrence are significantly closer in terms of global methylation
than a random pair of samples taken from two different
individuals, both in the PT/AM cohort (P-value = 3:5  10{7)
and in the PT/LR cohort (P-value = 1:6  10{6). This is however
not true in the PT/CL cohort, where we detect no differences
between correctly and randomly matched pairs (P-value = 0:44).
Table 3. Summarized PT/AM Clinical and histological features.
Pair Age Type Grade ER PR HER2
1 45.9 D 3 + + -
2 NA D 3 + + -
3 NA NA NA + + -
4 48.8 D 1 + + -
5 43.6 D 3 - - -
6 35.3 D 2 + + -
7 45.1 D 3 + + -
8 41.9 D 2 + + NA
9 43.5 D 1 + + -
10 43.7 D 3 + + NA
11 44.9 D 2 - - -
12 43.6 D 1 + - -
13 40.2 D 3 - - +
14 32.5 L 3 + + +
15 38.5 D 2 - + -
16 37.5 D 3 + + -
17 39.3 D 3 + + -
18 37.6 D 3 - - -
19 36.6 D 3 + + +
20 35.4 D 3 - + -
Age: Age of the patient at diagnosis of the primary tumor in years, Type: histological type of the tumor (D = ductal, L = lobular, Meta =Metaplasia), Grade:
Aggressiveness of the tumor (1 to 3), ER: presence of estrogen receptors, PR: presence of progesterone receptors, HER2: presence of HER2 receptors.
doi:10.1371/journal.pone.0103986.t003
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Table 4. Significantly differentially methylated genes between PT and AM samples.
CpG Gene Pvalue Methylation Variation
cg20161089 IFI27 0.013 0.238
cg18140857 RDHE2 0.013 0.102
cg04619381 LOC222171 0.013 20.048
cg23698969 SLC22A18 0.013 0.042
cg16179125 CTSZ 0.020 0.182
cg24959428 GBP6 0.020 0.126
cg22630748 INHBE 0.020 0.100
cg03623878 MCF2L 0.020 20.050
cg25115460 TP73 0.022 0.109
cg11946165 CTSK 0.022 0.098
cg01318557 LAT2 0.022 0.063
cg13453139 PIK3R5 0.022 20.063
cg21416237 FKBP10 0.028 0.085
cg19814116 KCNAB2 0.031 20.217
cg22392666 FXYD7 0.031 20.217
cg18212039 EXTL1 0.031 0.106
cg03532879 SMAF1 0.031 0.041
cg27149093 SLC41A2 0.032 0.145
cg18946226 MYR8 0.032 0.139
cg15448245 GGTLA1 0.032 0.132
cg15792367 KLK11 0.032 0.111
cg07459489 SLC30A8 0.032 0.085
cg15021292 PIK3R1 0.032 0.075
cg26267561 OXT 0.032 0.072
cg08647446 RASSF6 0.032 20.070
cg20967028 ART4 0.032 20.062
cg08550724 C6orf182 0.032 0.052
cg09737668 SLAMF9 0.032 0.049
cg23036025 SLC27A5 0.032 0.047
cg15296858 PPM1G 0.032 0.038
cg04961553 OCIAD2 0.032 20.018
cg17558126 RASSF5 0.038 20.137
cg06852652 CYP2C18 0.038 0.055
cg05840031 PAX6 0.038 20.031
cg15043801 DNMT1 0.038 20.016
cg05649009 CHRNA1 0.046 0.171
cg16176379 AYTL1 0.046 20.128
cg05538432 C1S 0.046 0.123
cg25151295 RANBP5 0.046 0.121
cg23841186 SOAT2 0.046 0.096
cg05656364 VAMP8 0.046 20.085
cg14833385 HLA-DMA 0.046 20.085
cg27655855 CST9L 0.046 0.084
cg27461196 FXYD1 0.046 0.069
cg14106308 VEPH1 0.046 20.056
cg22857604 RASSF5 0.046 20.053
cg10891879 CASZ1 0.046 20.029
cg25042226 PAX8 0.046 20.025
cg11655418 RPS10 0.046 0.005
CpG: CpG probe name. Gene: Associated gene. Pvalue: FDR corrected p-value.Methylation Variation: Mean variation of methylation from the primary tumor to the
axillary metastasis.
doi:10.1371/journal.pone.0103986.t004
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In addition, we calculated the distribution of distances between the
CL tumors. We performed the same analysis between the PT
tumors. We observed that the distribution were not significantly
different (P-value = 0:52), as expected. This is in agreement with
the assumption we made that CL tumors could be considered as
new primary tumors. Finally, we also compared the distribution of
distances between the healthy breast tissue i and all the other
healthy breast tissues from the cohort to assess the heterogeneity
between normal breast tissues.
Clonality detection based on methylation profiles
The above results suggests that methylation profiles tend to be
conserved during clonal expansion (such as samples in the PT/AM
cohort), but strongly differ between unrelated tumors in a given
person (such as samples in the PT/CL cohort). Moreover,
methylation seems to be a stable mechanism in normal tissues
compared to cancerous ones. It is therefore tempting to use
methylation distance as a tool to discriminate true recurrences
from new tumors in ambiguous cases, that is, for samples in the
PT/LR cohort.
9 out of 17 PT/LR pairs (52%) have a MS score higher than the
threshold given by the 95% percentile of the MS score between
unrelated pairs (MSThreshold~ 6:6  10{4) as shown in Figure 5;
they are therefore considered as clonal pairs from the methylation
point of view. The remaining 8 pairs are considered as non-clonal,
meaning that the LR may correspond to a new primary tumor.
Figure S2 shows how related pairs are similar compared to
unrelated pairs for the PT/AM (Panel A) and PT/CL (Panel B)
groups.
Comparison between the methylation-based similarity measure
MS score with the partial identity score (PIS), a copy-number
based similarity measure developed by [16] show a good
correlation overall (r ~ 0:55, P-value = 3:7  10{5, see Figure 6).
Table 5 gives a comparison of the outcomes given by methylation-
based, copy-number based and clinical-based classification of LR
as TR or NP. The methylation-based classification method agreed
with the copy-number based PIS classification method on 14 out
of 17 pairs (concordance = 82% , P-value = 6:3  10{3) and agreed
with the clinical-based classification on 14 out of 17 pairs
(concordance = 82% , P-value = 6:3  10{3).
Figure 1. Accuracy of multivariate analysis with respect to feature selection to classify primary tumors from locoregional
evolutions. Accuracy to classify PT from AM (resp. LR, resp. CL.) is represented in yellow (resp. blue, resp. pink).
doi:10.1371/journal.pone.0103986.g001
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Finally, the different classifications of LR as TR or NP were
correlated with time-to-recurrence and metastasis-free survivals.
The differences in time-to-recurrence for the two groups defined
by methylation-based classification or the clinical and histological
classification were not statistically significant (P-value = 0:83 and
P-value = 0:12). It was however significant using the partial
identity score (P-value = 0:03) (Figure S3). This is interesting in
the sense that one of the main criteria to distinguish TR and NP is
the time-to-recurrence. Therefore, methylation-based classifica-
tion is based on more information than time only.
The difference in metastasis-free survival of patients with TR
and NP was not significant based on methylation (P-value = 0:52,
Hazard-Ratio = 3:7, 5 year metastasis-free survival = 75% for
NP), copy-number (P-value = 0:15, Hazard-Ratio = 16:9, 5 year
metastasis-free survival = 86% for NP) or clinical features (P-
value = 0:17, Hazard-Ratio = 6:3, 5 year metastasis-free
survival = 86% for NP) (Figure 7). Adjusting for age, grade and
ER status did not yield more significant results except for copy-
number based classification (P-value = 0:46, Table S6).
Discussion
We studied alterations of methylation profiles from primary
breast carcinomas and different types of recurrences, namely,
axillary metastases, local recurrences and contralateral breast
carcinomas. For this particular dataset, we observed significant
methylation differences for 49 CpG probes, which characterizes
the progression between a PT and its AM. Consistent with this
result, a multivariate analysis with a linear SVM classifier using a
small subset of probes perfectly distinguished PTs from AMs with
a 100% accuracy. Several significantly differentially methylated
probes correspond to genes involved in cancer-related mechanisms
such as cell death (MCF2L, RASSF5, RASSF6, CASZ1,
SLC22A18, IFI27), tumorogenesis (CTSZ, TP73, CTSK,
PIK3R1), KLK11, cell cycle (PPM1G, RANBP5, VAMP8) and
cell differentiation (SMAF1, PAX6, PAX8). On the contrary, for
the PT/LR and PT/CL sets, univariate analyzes were not able to
find significantly differentially methylated probes. This absence of
specific epigenetic alterations between the primary tumors and the
Figure 2. Study of similarity between matched primary tumors and recurrences by hierarchical clustering. Hierarchical clustering based
on the manhattan distance between methylome profiles with complete linkage was performed. Real pairs that are closer to each other than to any
other samples are underlined. Panel A (resp. B, resp. C) represents the PT/AM (resp. PT/LR, resp. PT/CL) set.
doi:10.1371/journal.pone.0103986.g002
Figure 3. Distribution of methylation distances between different samples pairs for each groups. Real: boxplot of methylome distances
for all matched pairs that is a PT and its corresponding metastasis or recurrence. Artificial: boxplot of methylome distances for all unmatched pairs
that is a PT and an unrelated metastasis or recurrence. Primary: boxplot of methylome distances to distances between two PT of two different
individuals. Recurrence: boxplot of methylome distances between two metastasis or recurrence samples of two different individuals.
doi:10.1371/journal.pone.0103986.g003
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local recurrences or the contralateral breast recurrences was
confirmed by the poor performances of linear classifiers, unable to
separate PT from LR nor PT from CL significantly better than
random guesses. Nevertheless, the absence of methylation markers
in the PT/LR and the PT/CL groups does not necessarily mean
that the primary tumor and the recurrence are independent. We
cannot rule out the possibility that the recurrence arises from a
specific subclone which does not match the major subclone of the
primary tumor. One could for example analyze the methylation
profiles of several microdissections samples of the primary tumor
to study potential heterogeneity.
The second part of the study focused on observing stability in
methylation profiles. It is interesting to note that although PTs and
AMs were significantly differentiable using a subset of probes, they
also have overall very similar methylation profiles indicating that
the tumors might actually be clones with specific alterations
characteristic of the lymph node status. The subset of genes
determined in the first part, if confirmed, could be associated with
bad prognosis. On the other part, although the LRs and the CLs
were not significantly different from their primary tumors, they
tend to have overall different methylome profiles especially for the
CLs. The overall different methylome profiles for the PT/CL set
was expected since CLs are usually considered to be independent
tumors.
The results above suggested to use global methylation analysis
as a measure of clonality to tackle the subclonal populations in the
local recurrences as proposed by Veronesi et al. [9]. A
methylation-based classification was proposed to distinguish LRs
as either true recurrences of the first PT or new PT [10]. A
comparison with both clinical and copy-number based classifica-
tions on the same cohorts agreed on 14 out of 17 samples (82%
concordance, P-value = 6:410{3) for both methods, although
comparisons on larger cohorts are needed to assess the perfor-
mance of methylation-based classification. Moreover, a good
correlation between the methylation-based similarity score and the
copy-number based similarity score seems to indicate a link
between modifications at the genomic and epigenomic levels.
Although the role of methylation in gene expression has
thoroughly been studied [24–26], the relationship between
methylation and copy-number still remains unclear. Houseman
et al. [33] note that there is a negative bias of methylation when
one or both alleles are lost but none in case of gains. Several other
studies have reported correlation between the two mechanisms in
different types of cells. Strong associations have been reported in
urothelial carcinoma [34], head and neck squamous cell carcino-
Figure 4. Pairwise methylome distance for each samples. Each boxplot represents the Manhattan distance between primary tumor i and an
unrelated locoregional evolution, or the Manhattan distance between locoregional evolution i and an unrelated primary tumor. The black square
represent the Manhattan distance between the matched primary tumor and locoregional evolution from sample i. The yellow (resp. blue, resp. pink)
panel represents the PT/AM (resp. PT/LR, resp. PT/CL) set. The last panel represents the distribution of distances between the healthy breast tissue i
and all the other healthy breast tissues from the cohort.
doi:10.1371/journal.pone.0103986.g004
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mas [35], and mesothelioma [36]. Our study provides new
evidence for association between methylation and copy-number
on a global scale.
The discordances between the methylation-based classification
method and the usual clinical method are discussed here for the
samples 7, 8 and 14, although no actual method is a gold standard
for classifying TR from NP. Sample 8 filled almost all the
requirements for clinical classification as TR (location, receptor
status) but failed in aggressiveness and type of tumor (PT was
ductal type 2 and LR was lobular type 1). A decrease of
aggressiveness of the recurrence could be explained by the use of
neoadjuvant therapies. For the change of type, Fisher et al. showed
that a mixing of ductal and lobular breast carcinoma was a
possibility in 6% of the patients [37] which could explain the
change in type. Sample 7 was classified as TR by clinical
classification and as NP by both methylation and copy-number
based classifications. This suggests some limitations to methods
based only on clinical features.
An interesting question for clinical applications would have
been to predict whether a primary tumor would relapse (either as
AM, LR or CL) or not. However, the patient cohort used in this
study does not allow to address this question. Indeed, one would
require to compare the methylation profiles of patients who did
not display any relapse (AM, LR and CL) to those of the current
study.
Materials and Methods
Patients Selection
The patients were 49 years old or younger at diagnosis of the
initial tumor; all patients were premenopausal; and had no
previous history of cancer, except for one nonmelanoma skin
cancer. The patients’ PT was either ductal or lobular invasive
breast carcinoma. However, both types of tumors did not display
significantly differentially methylated probes and were thus all
included in this study (min P-value§ 0:89).
Specimens from patients with primary breast cancers and breast
cancer recurrences were selected from freshly frozen samples of
the Institut Curie tissue bank according to the following criteria: all
patients had been treated at the Institut Curie by breast-
Figure 5. Histogram of the distribution of methylome-similarity score (MS) between unrelated PT/LR pairs. MS score for matched pairs
is represented by circles. The vertical dashed line corresponds to the 95% quantile of the distribution of the MS scores for the unrelated pairs, used as
a threshold to define clonal pairs (MSThreshold~ 6:6  10{4).
doi:10.1371/journal.pone.0103986.g005
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conserving surgery, including dissection of the axillary lymph
nodes in most patients, followed by radiotherapy to the breast with
or without a boost to the tumor bed (external beam radiotherapy
or brachytherapy) and/or to the regional lymph node-bearing
areas if indicated and, when required, systemic treatment as part
of their initial management. Methylation profiles did not
significantly differ depending on either ER, PR, HER2 and grade
characteristics (min adjusted P-value = 0:09).
To ensure that the data would be informative, genomic analyzes
were restricted to tumors (primary and recurrences) in which at
least 50% of cancer cells had been assessed by hematoxylin, eosin,
and saffron staining of sections from snap-frozen samples. All the
therapies were performed posterior to the biopsies of the primary
tumors. Therefore, the studied methylation profiles are not
modified by any potential effect of the treatments.
The 22 healthy breast tissues are taken from healthy women
who underwent cosmetic plastic surgery at the Institut Curie. Part
of the PT/AM cohort is identical to the cohort studied by Bollet et
al. [16].
All experiments were performed retrospectively and in accor-
dance with the French Bioethics Law 2004–800, the French
National Institute of Cancer (INCa) Ethics Charter and after
approval by the Institut Curie review board and ethics committee
(Comit de Pilotage of the Groupe Sein). In the French legal
context, our institutional review board waived the need for written
informed consent from the participants. Moreover, women were
informed of the research use of their tissues and did not declare
any opposition for such researches. Data were analyzed anony-
mously.
Methylation profiling
For each sample the methylation status at 27,578 positions in
the genome was measured with the HumanMethylation27
BeadChip of Infinium technology [38] using the standard Illumina
Figure 6. Correlation between methylation and copy-number scores. The horizontal red line (resp. vertical dashed blue line) corresponds to
the 95% quantile of the distribution of the methylation-scores (resp. partial identity scores) for the unrelated pairs: MSThreshold~ 6:6  10{4 (resp.
PISThreshold~ 0:12). PT/AM (resp. PT/LR, resp. PT/CL) pairs are colored in yellow (resp. blue, resp. pink). The black line corresponds to the linear
regression between methylation and copy-number scores for all the datasets.
doi:10.1371/journal.pone.0103986.g006
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protocol. Quality control was assessed using in-built Illumina
technology.
Copy number based classification
The PIS score, based on copy number alterations similarities
between the primary tumor and its recurrence, was retrieved from
[16] for the same population.
Clinical Classification
Histopathologic characteristics were reviewed by a single
pathologist. The histological and biological properties of each
sample was determined by subjecting tissue sections to immuno-
histochemical analysis for the estrogen receptor (clone 6F11, 1:200
dilution; Novocastra, Newcastle Upon Tyne, England) and
progesterone receptor (clone 1A6, 1: 200 dilution; Novocastra)
antibodies. Tumors were considered to be positive for these
receptors if at least 10% of the invasive tumor cells in a section
showed nuclear staining [39,40]. The HER2 analysis was
performed using the standard ASCO guidelines [41]. In accor-
dance with theories of the clonal evolution of tumor cell
populations, LR were clinically defined as TR if they had the
same histologic subtype (ductal or lobular) and a similar or
increased growth rate, similar estradiol, progesterone and HER2
receptor statuses, and similar or decreased differentiation as the
initial tumor [10]. TR also had to share with their PT the same
breast quadrant. Thus, new PT were clinically defined as such
when the LR had occurred in a different location, had a distinct
histologic type, or had less aggressiveness features (lower grade,
presence of hormonal receptors) than the initial tumor.
Data analysis
A spatial normalization process was applied to all profiles [42].
Among the 27,578 probes measured on each sample, 5 probes
were removed due to missing values for some individuals, and all
subsequent analysis was performed on the 27,573 remaining
probes.
Differentially methylated probes between PT and their matched
AM, LR and CL are obtained using two-sided paired and
unpaired Wilcoxon tests, correcting the p-values for multiple
testing with the methods of Benjamini and Hochberg [43].
Multivariate analysis was performed using a linear support vector
machine (SVM) multidimensional classifier on either the complete
methylation profile or after dimensional reduction by considering
only the most significant probes based on the Wilcoxon test. A p-
value was calculated to assess the significance of the predictor
accuracy compared to a predictor that would predict classes
randomly. Unsupervised classifications were performed with
complete linkage agglomerative clustering using the MATLAB
bioinformatics toolbox, while the support vector machine imple-
mented in LIBSVM [44] was computed with a linear kernel and
nested leave-one-out cross validation for parameter selection for
supervised classification.
The similarity between two copy number profiles is assessed
with the partial identity score (PIS) as defined by Bollet et al. [16],
which is based on the quantity of shared breakpoints between the
two profiles and their frequencies. Following [16], a recurrence
Figure 7. Kaplan-Meier estimates of the metastasis-free
survival between TR and NP for the different classification
methods. The full black (resp. green) line corresponds to the survival
for samples classified as TR (resp. NP) and the corresponding dashed
lines correspond to upper and lower 95% CI. The red crosses represent
censored data. Panel A (resp. B, resp. C) represent the methylation-
based (resp. copy-number based, resp. clinical based) classification.
doi:10.1371/journal.pone.0103986.g007
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from a matched PT/LR pair was considered TR based on copy
numbers when the PIS between the PT and LR profiles was above
the 95% quantile of the empirical PIS distribution between
unrelated sample pairs. Similarly, a Methylation-Similarity score
(MS) is defined based on the methylation profiles of a PT and its
matched LR as the inverse of the Manhattan distance between
their methylation profiles considered as 27,573-dimensional
vectors. LR are then classified as TR of its matched PT when
the MS score is above the 95% quantile of the empirical MS
distribution between unrelated pairs. As a baseline, these results
were compared to the Manhattan distance between unrelated
normal breast tissues.
Metastasis-free survival was estimated by the Kaplan-Meier
Method [45] and compared between the group of patients who
were diagnosed as TR and the group diagnosed as NP using the
log-rank test. The confidence interval of the hazard ratio was
obtained using a semi-parametric Cox model [46]. Computation
was done using MATLAB packages Logrank [47] and KMPlot
[48].
Supporting Information
Figure S1 Quantile-quantile plot of the Wilcoxon test
statistics for each groups. Plot of the data quantiles (black
dots) against normal theoretical quantiles. The red line is y~ x.
(TIF)
Figure S2 Histograms of the distribution of Methylome-
Similarity score (MS) between unrelated PT/AM and
PT/CL pairs. MS score for matched pairs is represented by
crosses for the PT/AM pairs (Panel A) and by stars for the PT/CL
pairs (Panel B). The vertical dashed line corresponds to the 95%
quantile of the distribution of the MS scores for the unrelated
pairs.
(TIF)
Figure S3 Correlation between time to recurrence and
classification of the recurrence. Boxplots of time between
the primary tumor and the local recurrence depending on the
classification as true recurrence (TR) or new primary tumor (NP)
according to the methylation-based, copy-number based (PIS) and
clinical based classification.
(TIF)
Table S1 Complete PT/LR Clinical and histological
features. Cor (Correspondence): correspondence number with
the Bollet/Servant cohort from [16], Type: histological type of the
tumor (D= ductal, L = lobular), Grade: Aggressiveness of the
tumor (1 to 3), ER: percentage of estrogen receptors, PR:
percentage of progesterone receptors present, HER2: presence of
HER2 receptors, Loc (Location): 1 if the recurrence was located
less than 4cm from the PT.
(TIF)
Table S2 Complete PT/CL Clinical and histological
features. Type: histological type of the tumor (D= ductal, L =
lobular, Med=Medullary, Meta=Metaplasic), Grade: Aggres-
siveness of the tumor (1 to 3), ER: percentage of estrogen receptors
present, PR: percentage of progesterone receptors present,
HER2: presence of HER2 receptors.
(TIF)
Table S3 Complete PT/AM Clinical and histological
features. Age: Age of the patient at diagnosis of the primary
tumor in years, Type: histological type of the tumor (D= ductal,
L = lobular, Meta=Metaplasia), Grade: Aggressiveness of the
tumor (1 to 3), ER: percentage of estrogen receptors present, PR:
percentage of progesterone receptor present, HER2: presence of
HER2 receptors.
(TIF)
Table S4 Top 50 CpG loci between PT and LR samples.
CpG: CpG probe name. Gene: Associated gene. Pvalue: FDR
corrected p-value. Methylation Variation: Mean variation of
methylation from the primary tumor to the local recurrence.
(TIF)
Table S5 Top 50 probes between PT and CL samples.
CpG: CpG probe name. Gene: Associated gene. Pvalue: FDR
corrected p-value. Methylation Variation: Mean variation of
methylation from the primary tumor to the contralateral
recurrence.
(TIF)
Table S6 Predictive impact of the classification meth-
ods on survival in breast cancer. Variables: variable
considered for predictive impact adjusted for the other variables
present in the table. Coef: Associated coefficient in the Cox
regression. lower/upper .95: lower and upper 95% confidence
interval. Pvalue: P-value associated with the predictive impact on
survival.
(TIF)
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